Augmentation of the therapeutic activity of lometrexol [(6-R)5,10-Dideazatetrahydrofolate] by oral folic acid

Cancer Research

Volumn 56, Issue 10, 1996, Pages 2331-2335

  Alati, Teresa ^a   Worzalla, John F ^a   Shih, Chuan ^a   Bewley, Jesse R ^a   Lewis, Sidney ^b   Moran, Richard G ^c   Grindey, Gerald B ^a  

^a ELI LILLY AND COMPANY   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; LOMETREXOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; TETRAHYDROFOLATES;

EID: 0029883293     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Taylor, E. C., Harrington, P. J., Fletcher, S. R., Beardsley, G. P., and Moran, R. G. Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin J. Med. Chem., 28: 914-921, 1935.
2. Beardsley, G. P., Moroson, B. A., Taylor, E. C., and Moran, R. G A new folate antimetabolite, 5,10-dideaza-5,6,7,8 tetrahydrofolate, is a potent inhibitor of de novo purine synthesis. J Biol Chem., 264. 328-333, 1989.
3. Moran, R G , Baldwin, S. W., Taylor, E. C., and Shih, C. The 6-S and 6-R diastereomers of 5,10-dideaza-5,6,7,8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J. Biol. Chem., 264: 21047-21051, 1989.
4. Baldwin, S W , Tse, A., Gossett, L. S , Taylor, E. C., Rosowsky, A , Shih, C., and Moran, R. G Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleootide formyltransferase Biochemistry, 30: 1997-2006, 1991.
5. Smith, S. G , Lehman, N. L., and Moran, R G. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res., 53: 5697-5706, 1993.
6. Pizzorno, G., Sokoloski, I. A., Cashmore, A. R., Moroson, B. A , Cross, A. D., and Beardsley, G. P. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines. Mol. Pharmacol , 39: 85-89, 1991
7. Brigle, K. E., Spinella, M. J., Westin, E. H., and Goldman, I. D Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochem. Pharmacol , 47: 337-345, 1994.
8. Jansen, G , Westerhof, G. R., Kathmann, I , Rijksen, G., and Schornagel, J. H. Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for antifolate compounds. Cancer Chemother. Pharmacol., 28: 115-117, 1991.
9. Pizzorno, G., Cashmore, A. R., Moroson, B A., Cross, A. D , Smith, A K., Marling-Cason, M., Kamen, B , and Beardsley, G. P. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. J. Biol Chem., 268: 1017-1023, 1993
10. Shih, C , Grindey, G. B , Houghton, P. J., and Houghton, J. A In vivo antitumor activity of 5,10-dideazatetrahydrofolic acid (DDATHF) and its diastereomeric isomers. Proc Am Assoc. Cancer Res., 29: 283, 1988
11. Taylor, E. C. New pathways from pteridines. Design and synthesis of a new class of potent and selective antitumor agents J. Heterocycl. Chem , 27. 1-11, 1990.
12. Nelson, R., Butler, F , Dugan, W., Jr., Davis-Land, C., Stone, M., and Dyke, R. Phase I clinical trial of LY264618 (dideazatetrahydrofolic acid, DDATHF) Proc. Am. Soc. Clin. Oncol., 9: 76, 1990.
13. Young, C , Currie, V , Baltzer, L., Trochanowski, B., Eton, O., Dyke, R., and Bowsher, R. Phase I and clinical pharmacologic study of LY264618, 5,10-dideazatetra-hydrofolate. Proc. Am Assoc. Cancer Res., 31: 117, 1990.
14. Sessa, C., Gumbell, L , Hatty, S., Kern, H., and Cavalli, F Phase I study of 5,10-dideazatetrahydrofolic acid (LY264618, DDATHF) given daily for 3 consecutive days. Ann. Oncol., 1 (Suppl.): 38, 1990.
15. Ray, M. S., Muggia, F. M., Leichman, G. C , Grunberg, S. G., Nelson, R L., Dyke, R W., and Moran, R. G Phase I study of (6R) 5,10-dideaza-5,6,7,8-tetrahydrofolate-a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst. (Bethesda), 85: 1154-1159, 1993
16. Alan, T., Shih, C., Pohland, R C , Lantz, R. J , and Grindey, G. B Evaluation of the mechanism of inhibition of the toxicity, but not the antitumor activity, of lometrexol (DDATHF) by folic acid. Proc. Am. Assoc. Cancer Res , 33: 407, 1992
17. Grindey, G. B., Alati, T , and Shih, C Reversal of the toxicity but not the antitumor activity of lometrexol by folic acid. Proc. Am. Assoc. Cancer Res., 32: 324, 1991.
18. Young, C. W , Currie, V. E., Muindi, J. F., Saltz, L. B., Pisters, K. M. W., Esposito, A J , and Dyke, R. W. Phase I study of lometrexol (LY264618 or LTX)-improved clinical tolerance with folic acid. Proceedings of the 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, p. 136, 1992.
19. Wedge, S. R., Laohavinij, S., Taylor, G. A , Boddy, A., Calvert, A. H., and Newell, D. R Clinical pharmacokinetics of the antipurine antifolate (6A)-5,10-dideazatetrahydrofolate (lometrexol) administered with an oral folic acid supplement. Clin. Cancer Res , 1: 1479-1486, 1995
20. Geran, R. I., Greenberg, N. H., MacDonald, M. M., Schumacher, A. M., and Abbott, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep Part 3, 3: 51, 1972.
21. Worzalla, J. F., Bewley, J R., and Grindey, G B Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer Invest. New Drugs, 8: 241-251, 1990.
22. Sauberlich, H. E. Detection of folic acid deficiency in populations. In: H. P. Broquist, C E. Butterworth, Jr., and C. Wagner (eds.), Folic Acid: Biochemistry and Physiology in Relation to Human Nutritional Requirements, pp. 213-231. Washington DC: National Academy of Sciences, 1977.
23. Herbert, V. Making sense of laboratory tests of folate status: folate requirements to sustain normality. Am. J. Hematol., 26: 199-207, 1987.
24. 12 in patients with malignant hematologic diseases Cancer Res., 25: 1933-1938, 1965.
25. Halsted, C. H. Intestinal abruption and malabsorption of folates. Annu. Rev Med., 31: 79-87, 1980.
26. Olinger, E. J., Bertino, J. R., and Binder, H. J. Intestinal folate absorption. II. Conversion and retention of pteroylmonoglutamate by jejunum J. Clin. Invest., 52: 2138-2145, 1973
27. Taber, L D., O'Brien, P., Bowsher, R. R., and Sportsman, J. R. Competitive particle concentration fluorescence immunoassay for measuring 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) in seram. Clin. Chem., 37: 254-260, 1991.
28. Pohland, R. C , Alati, T., Lantz, R. J., and Grindey, G. B Whole-body autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets. J. Pharm. Sci., 83: 1396-1399, 1994.
29. Moran, R. G., and Colman, P. D. Measurement of folyl polyglutamate synthetase in mammalian tissue. Anal. Biochem., 140: 326-342, 1984.
30. Tse, A , and Moran, R G Control of the polyglutamation of 5,10-dideazatetrahydrofolate by intracellular folate pools: a novel mechanism of resistance to antifolates. Proc. Am. Assoc. Cancer Res., 35: 304, 1994.
31. Schmitz, J. C., Grindey, G. B., Schultz, R M., and Priest, D. G Impact of dietary folic acid on reduced folates in mouse plasma and tissues Relationship to dideazatetrahydrofolate sensitivity Biochem Pharmacol., 48: 319-325, 1994.
32. Kamen, B A., Nylen, P. A , Camitta, B M., and Bertino, J R Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug Br J Haematol , 49: 355-360, 1981
33. Kremer, J M , Galivan, J , Streckfuss, A., and Kamen, B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arthritis Rheum., 29, 832-835, 1986.